IP Library › Granted Patent US 10,632,140
Granted Patent B2
US 10,632,140 · App. 16/391,473 · Granted Apr 28, 2020

Methods relating to lung cancer

Inventors: Ana Brandusa Pavel (New York, NY); Joshua David Campbell (Sharon, MA); Marc Elliott Lenburg (Brookline, MA); Avrum Elliot Spira (Newton, MA)
Assignee: TRUSTEES OF BOSTON UNIVERSITY
A61K31/7105A61P35/00C12Q1/6825C12Q1/6886G01N33/57423C12Q2539/10C12Q2600/158C12Q2600/178
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,632,140
App. No.
16/391,473
Granted
Apr 28, 2020
Kind
B2
Abstract

The methods and assays described herein relate to detection, diagnosis, and treatment of lung cancer, e.g., by detecting the level of expression of certain miRNAs described herein and/or by therapeutically increasing the level of those miRNAs.

Claims (41)

1. A method comprising:

detecting the level of expression of miR-146a 5p

in a nasal epithelial sample obtained from a subject.

2. The method of claim 1 , wherein the subject is a mammal.

3. The method of claim 2 , wherein the subject is a human.

4. The method of claim 1 , wherein the subject is a current or former smoker.

5. The method of claim 1 , further comprising a first step of obtaining the sample.

6. The method of claim 1 , wherein the subject is at risk of developing lung cancer.

7. The method of claim 6 , wherein the lung cancer is non-small cell lung cancer.

8. The method of claim 1 , wherein the detecting step comprises sequencing of miRNAs in the sample.

9. The method of claim 1 , wherein the method further comprises detecting the expression level of one or more additional mRNAs.

10. The method of claim 1 , wherein the expression level of no more than 100 miRNAs and/or mRNAs is detected.

11. The method of claim 1 , wherein the level of expression is further detected for at least one miRNA selected from the group consisting of:

miR-324-5p, miR-223-3p, miR-223-5p; miR-450b-5p, miR-221-3p-miR-505-3p, and miR-582-5p.

12. The method of claim 1 , wherein the level of expression is further detected for at least two miRNAs selected from the group consisting of:

miR-324-5p, miR-223-3p, miR-223-5p; miR-450b-5p, miR-221-3p-miR-505-3p, and miR-582-5p.

13. The method of claim 1 , wherein the level of expression is further detected for at least three miRNAs selected from the group consisting of:

miR-324-5p, miR-223-3p, miR-223-5p; miR-450b-5p, miR-221-3p-miR-505-3p, and miR-582-5p.

14. The method of claim 1 , wherein the level of expression is further detected for at least four miRNAs selected from the group consisting of:

miR-324-5p, miR-223-3p, miR-223-5p; miR-450b-5p, miR-221-3p-miR-505-3p, and miR-582-5p.

15. The method of claim 1 , wherein the level of expression is further detected for at least five miRNAs selected from the group consisting of:

miR-324-5p, miR-223-3p, miR-223-5p; miR-450b-5p, miR-221-3p-miR-505-3p, and miR-582-5p.

16. The method of claim 1 , wherein the level of expression is detected for at least six miRNAs selected from the group consisting of:

miR-324-5p, miR-223-3p, miR-223-5p; miR-450b-5p, miR-221-3p-miR-505-3p, and miR-582-5p.

17. The method of claim 1 , wherein the level of expression is further detected for miR-324-5p, miR-223-3p, miR-223-5p; miR-450b-5p, miR-221-3p-miR-505-3p, and miR-582-5p.

18. The method of claim 1 , wherein the level of expression is detected for at least miR-146a-5p, miR-324-5p, miR-223-3p, and miR-223-5p.

19. A method comprising:

detecting the level of expression of at least miR-146a-5p; miR-324-5p; miR-223-3p; and miR-223-5p in a sample obtained from a subject,

wherein the expression level of no more than 100 miRNAs is detected.

20. The method of claim 19 , further comprising detecting the level of expression of at least 1 miRNA selected from the group consisting of:

miR-450b-5p; miR-221-3p; miR-505-3p; and miR-582-5p in the sample obtained from a subject.

21. The method of claim 19 , wherein the subject is a mammal.

22. The method of claim 21 , wherein the subject is a human.

23. The method of claim 19 , wherein the subject is a current or former smoker.

24. The method of claim 19 , further comprising a first step of obtaining the sample.

25. The method of claim 19 , wherein the sample is a bronchial brushing or nasal epithelial sample.

26. The method of claim 19 , wherein the subject is at risk of developing lung cancer.

27. The method of claim 26 , wherein the lung cancer is non-small cell lung cancer.

28. The method of claim 19 , wherein the detecting step comprises sequencing of miRNAs in the sample.

29. The method of claim 19 , wherein the method further comprises detecting the expression level of one or more mRNAs.

30. The method of claim 19 , wherein the level of expression is detected for miR-146a-5p, miR-324-5p, miR-223-3p, miR-223-5p; miR-450b-5p, miR-221-3p-miR-505-3p, and miR-582-5p.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2019
From: PAVEL, ANA BRANDUSA; CAMPBELL, JOSHUA DAVID; LENBURG, MARC ELLIOT; SPIRA, AVRUM
To: TRUSTEES OF BOSTON UNIVERSITY
Reel/Frame 048983/0513 →
Continuity (3)
Continuation 15877447 · Jan 23, 2018
Provisional Application 62449223 · Jan 23, 2017
Related Publication 20190247418A1 · Aug 15, 2019